MXPA02008255A - Acidos orto-sulfonamido aril hidroxamicos proceso para su preparacion y su uso como inhibidores de metaloproteinasa de matriz. - Google Patents
Acidos orto-sulfonamido aril hidroxamicos proceso para su preparacion y su uso como inhibidores de metaloproteinasa de matriz.Info
- Publication number
- MXPA02008255A MXPA02008255A MXPA02008255A MXPA02008255A MXPA02008255A MX PA02008255 A MXPA02008255 A MX PA02008255A MX PA02008255 A MXPA02008255 A MX PA02008255A MX PA02008255 A MXPA02008255 A MX PA02008255A MX PA02008255 A MXPA02008255 A MX PA02008255A
- Authority
- MX
- Mexico
- Prior art keywords
- ortho
- preparation
- hydroxamic acids
- matrix metalloproteinase
- metalloproteinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51380800A | 2000-02-25 | 2000-02-25 | |
PCT/US2001/005349 WO2001062733A1 (en) | 2000-02-25 | 2001-02-19 | Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02008255A true MXPA02008255A (es) | 2004-04-05 |
Family
ID=24044749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02008255A MXPA02008255A (es) | 2000-02-25 | 2001-02-19 | Acidos orto-sulfonamido aril hidroxamicos proceso para su preparacion y su uso como inhibidores de metaloproteinasa de matriz. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1259488A1 (ja) |
JP (1) | JP2003524000A (ja) |
CN (1) | CN1411446A (ja) |
AR (1) | AR027943A1 (ja) |
AU (1) | AU2001241578A1 (ja) |
BR (1) | BR0108633A (ja) |
CA (1) | CA2401013A1 (ja) |
MX (1) | MXPA02008255A (ja) |
WO (1) | WO2001062733A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10300015A1 (de) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen |
KR20130140688A (ko) * | 2010-09-24 | 2013-12-24 | 랜박시 래보러터리스 리미티드 | 기질 메탈로프로테나제 저해제 |
CN113194954A (zh) | 2018-10-04 | 2021-07-30 | 国家医疗保健研究所 | 用于治疗角皮病的egfr抑制剂 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL129147A0 (en) * | 1996-10-16 | 2000-02-17 | American Cyanamid Co | The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
AU743901B2 (en) * | 1996-10-16 | 2002-02-07 | Wyeth Holdings Corporation | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors |
EP1144369B1 (en) * | 1999-01-27 | 2004-07-21 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
-
2001
- 2001-02-14 AR ARP010100661A patent/AR027943A1/es unknown
- 2001-02-19 MX MXPA02008255A patent/MXPA02008255A/es unknown
- 2001-02-19 EP EP01912836A patent/EP1259488A1/en not_active Withdrawn
- 2001-02-19 JP JP2001562515A patent/JP2003524000A/ja active Pending
- 2001-02-19 CA CA002401013A patent/CA2401013A1/en not_active Abandoned
- 2001-02-19 WO PCT/US2001/005349 patent/WO2001062733A1/en not_active Application Discontinuation
- 2001-02-19 BR BR0108633-2A patent/BR0108633A/pt not_active IP Right Cessation
- 2001-02-19 AU AU2001241578A patent/AU2001241578A1/en not_active Abandoned
- 2001-02-19 CN CN01805552A patent/CN1411446A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
AR027943A1 (es) | 2003-04-16 |
JP2003524000A (ja) | 2003-08-12 |
BR0108633A (pt) | 2002-12-10 |
AU2001241578A1 (en) | 2001-09-03 |
CN1411446A (zh) | 2003-04-16 |
CA2401013A1 (en) | 2001-08-30 |
WO2001062733A1 (en) | 2001-08-30 |
EP1259488A1 (en) | 2002-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2001002240A0 (en) | Sufamato hydroxamic acid metalloprotease inhibitor. | |
EA200101085A1 (ru) | Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз | |
GB9801690D0 (en) | Therapeutic agents | |
NZ516562A (en) | Pyrimidine-2,4,6-trione metalloproteinase inhibitors | |
ZA200005217B (en) | α-sulfonylamino hydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders. | |
BG102918A (en) | Biphenylsulphanomide inhibitors of the matrix metalloproteinase | |
WO2000061167A3 (en) | TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS | |
MXPA04004803A (es) | Acidos hidroxamicos de sulfonas aromaticas y su uso como inhibidores de la proteasa. | |
NZ515197A (en) | Hydroxamic acid derivatives useful as matrix metalloprotease inhibitors | |
MXPA03010326A (es) | Sulfona-hidroxamatos aromaticos y su uso como inhibidores de proteasas. | |
YU71604A (sh) | Oksa-i tijadijazoli i njihova upotreba kao inhibitora metalo proteinaze | |
TR200101245T2 (tr) | N-arilsulfonil-aminoasit-omega-amidler | |
BR0011801A (pt) | Inibidores de benzamida substituìda para 3c protease de rinovìrus | |
IL146543A0 (en) | Inhibitors of metalloproteinases | |
MXPA02008255A (es) | Acidos orto-sulfonamido aril hidroxamicos proceso para su preparacion y su uso como inhibidores de metaloproteinasa de matriz. | |
ATE254118T1 (de) | Hydroxamsäure derivate | |
NO20003828L (no) | 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepin-3-hydroksamsyrer som matriks-metalloproteinase inhibitorer | |
PL357084A1 (en) | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | |
AU2001250573A1 (en) | Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone | |
TW200509921A (en) | Alkaline salts | |
TW200505910A (en) | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | |
MXPA02004699A (es) | Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco. | |
AU2001250571A1 (en) | Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol | |
IL160068A0 (en) | Mew mandelic acid derivatives and their use as thrombin inhibitors | |
FR2784582B3 (fr) | Nouvelle utilisation therapeutique de composes a activite beta-3-agoniste |